- Home
- BCS vs ARGX Comparison
BCS vs ARGX Comparison
Compare BCS & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCS
- ARGX
- Stock Information
- Founded
- BCS 1690
- ARGX 2008
- Country
- BCS United Kingdom
- ARGX Netherlands
- Employees
- BCS N/A
- ARGX N/A
- Industry
- BCS Commercial Banks
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCS Finance
- ARGX Health Care
- Exchange
- BCS Nasdaq
- ARGX Nasdaq
- Market Cap
- BCS 45.4B
- ARGX 37.3B
- IPO Year
- BCS N/A
- ARGX 2017
- Fundamental
- Price
- BCS $13.09
- ARGX $623.82
- Analyst Decision
- BCS
- ARGX Strong Buy
- Analyst Count
- BCS 0
- ARGX 20
- Target Price
- BCS N/A
- ARGX $634.50
- AVG Volume (30 Days)
- BCS 12.2M
- ARGX 290.3K
- Earning Date
- BCS 02-13-2025
- ARGX 10-31-2024
- Dividend Yield
- BCS 3.18%
- ARGX N/A
- EPS Growth
- BCS N/A
- ARGX N/A
- EPS
- BCS 0.37
- ARGX N/A
- Revenue
- BCS $31,629,808,326.00
- ARGX $1,908,659,000.00
- Revenue This Year
- BCS N/A
- ARGX $61.99
- Revenue Next Year
- BCS $5.49
- ARGX $42.48
- P/E Ratio
- BCS $8.28
- ARGX N/A
- Revenue Growth
- BCS N/A
- ARGX 85.56
- 52 Week Low
- BCS $7.07
- ARGX $349.86
- 52 Week High
- BCS $13.83
- ARGX $644.97
- Technical
- Relative Strength Index (RSI)
- BCS 46.65
- ARGX 58.04
- Support Level
- BCS $13.51
- ARGX $613.95
- Resistance Level
- BCS $13.58
- ARGX $644.97
- Average True Range (ATR)
- BCS 0.23
- ARGX 14.33
- MACD
- BCS -0.08
- ARGX -0.42
- Stochastic Oscillator
- BCS 27.25
- ARGX 50.28
About BCS Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via five principal segments; UK (retail), UK corporate bank, private bank and wealth management, investment bank, and us consumer bank. In its UK segment, the bank provides current accounts, mortgages, savings and investment management services, credit cards, and business banking services to retail clients and small and medium-size enterprises. The international segment includes a corporate bank offering banking solutions to large corporates, a bulge-bracket global investment bank, and a credit card and payments business.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.